[HTML] sciencedirect.com

[HTML][HTML] Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial …

CN Sternberg, Y Loriot, N James, E Choy… - European urology, 2019 - Elsevier
Background Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …
被引用次数：135 相关文章

[引用][C] Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial …

CN Sternberg, Y Loriot, N James, E Choy… - European Urology, 2019 - cir.nii.ac.jp
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy
for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract …

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial …

CN Sternberg, Y Loriot, N James, E Choy… - European …, 2019 - europepmc.org
Background Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …
[PDF] tecentriq.global

[PDF][PDF] Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial …

CN Sternberg, Y Loriot, N James, E Choy… - EUROPEAN …, 2019 - tecentriq.global
Background: Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial …

CN Sternberg, Y Loriot, N James, E Choy… - … , vol. 76, num. 1, p. 73 …, 2019 - diposit.ub.edu
Background: Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial …

CN Sternberg, Y Loriot, N James, E Choy… - European …, 2019 - research.uni-luebeck.de
Background: Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …
[PDF] archive.org

[PDF][PDF] Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial …

CN Sternberg, Y Loriot, N James, E Choy… - EUROPEAN …, 2019 - scholar.archive.org
Background: Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial …

CN Sternberg, Y Loriot, N James, E Choy… - European …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …

[引用][C] Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial …

CN Sternberg, Y Loriot, N James… - European …, 2019 - produccioncientifica.ucm.es
Background: Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …

Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of …

CN Sternberg, Y Loriot, N James, E Choy… - European …, 2019 - orca.cardiff.ac.uk
Background Atezolizumab, a humanised monoclonal antibody targeting PD-L1, is approved
for locally advanced/metastatic urothelial carcinoma. SAUL evaluated atezolizumab in a …